Abstract：Objective: To study the effects of hemodialysis (HD) and hemofiltration (HF) on cardiovascular stability in patients with chronic renal failure (CRF).Methods: A total of 104 CRF patients who underwent blood purification treatment from August 2018 to August 2019 were selected for the study and were randomly divided into CVVH group and HD group (each n=52).The two groups were given routine symptomatic support, and CVVH group was given CVVH on this basis, and HD group was given MHD, and the two groups were treated for 3 months.The dialysis effects, expression levels of inflammatory factors, hemodynamic indexes and prognosis were compared between the two groups.Results: After 3 months treatment, there were no significant differences in the GFR, Kt/V, nPCR and TACU between the two groups (P>0.05).Serum Scr and BUN levels were significantly decreased in the two groups (P<0.05), and the levels of serum PTH and β2-MG were significantly decreased in CVVH group (P<0.05), and the levels of PTH and β2-MG in CVVH group were lower than those in HD group (P<0.05).The serum IL-10 level in the two groups was significantly increased (P<0.05) while the levels of serum CRP and IL-6 levels were significantly decreased (P<0.05), and the level of IL-10 in CVVH group was higher than that in HD group while the levels of CRP and IL-6 were lower than those in HD group (P<0.05).The GEDVI The ITBVI and EVLWI were significantly decreased in the two groups (P<0.05), and the GVVI, ITBVI and EVLWI in CVVH group were lower than those in HD group (P<0.05).Results of 3 years follow-up showed that the incidence rates of CVD in CVVH group and HD group were 32.69% and 53.85% (P<0.05), and the cardiogenic death rates were 15.38% and 28.85% respectively (P>0.05).Conclusion: HD and CVVH can effectively promote the clearance of small molecule toxins in CRF patients, and CVVH has a good scavenging effect on medium macromolecular toxins, and it is beneficial to improve the body microinflammation states and maintain cardiovascular stability, thereby reducing the risk of adverse events such as CVD and cardiac death.
王知音, 何敏, 万俊. 血液透析和血液滤过对慢性肾功能衰竭患者心血管稳定性的影响[J]. 河北医学, 2020, 26(9): 1522-1527.
WANG Zhiyin, HE Min, WAN Jun. Study of the Effects of Hemodialysis and Hemofiltration on Cardiovascular Stability in Patients with Chronic Renal Failure. HeBei Med, 2020, 26(9): 1522-1527.
[1] Ketteler M,Block GA,Evenepoel P,et al.Executive summary of the 2017 KDIGO chronic kidneydisease-mineral and bone disorder(CKD-MBD) guideline update:what's changed and why it matters[J].Kidney Int,2017,92(1):26~36. [2] Li X,Xu H,Xiao XC,et al.Prognostic effect of high-flux hemodialysis in patients with chronickidney disease[J].Braz Jo Med Biol Res,2016,49(1):e4708. [3] Susanne S,Louise S,Azam NS,et al.Fluid balance-adjusted creatinine at initiation of continuous venovenous hemofiltration and mortality.A post-hoc analysis of a multicenter randomized controlled trial.[J].PLoS One,2018,13(6):e0197301. [4] Stevens PE,Levin A.Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline[J].Ann Intern Med,2013,158(11):825~830. [5] 鲁珍珍,陈万佳,刘旺意,等.中医内治法和外治法治疗慢性肾衰竭的研究进展[J].中国中西医结合肾病杂志,2018,19(3):277~279. [6] 陈香美,孙雪峰,蔡广研.我国慢性肾脏病防治的公共健康政策思考[J].中华医学杂志,2014,94(4):241~243. [7] Yotsueda R,Taniguchi M,Tanaka S,et al.Cardiothoracic ratio and all-cause mortality and cardiovascular disease events in hemodialysis patients:the Q-cohort study[J].Am Kidney Dis,2017,70(1):84~92. [8] Wong LS,Wu T,Lee CH.Inflammatory and noninflammatory Itch:implications in pathophysiology-directed treatments[J].Int Mol Sci,2017,18(7):E1485~E1489. [9] Sarah C,Seon JH,Eun CD,et al.The impact of hemodialysis and arteriovenous access flow on extracranial hemodynamic changes in end-stage renal disease patients:[J].Korean Med Sci,2016,31(8):1239~1245. [10] 刘军,徐建伟,刘雪梅.高通量血液透析对维持性血液透析患者心功能的影响[J].中国中西医结合肾病杂志,2015,16(5):433~435.
2020, Vol. 26 
冀公网安备13080202000677号